Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X3GA
|
|||
| Former ID |
DNCL003665
|
|||
| Drug Name |
NN8717
|
|||
| Indication | Graft-versus-host disease [ICD-11: 4B24; ICD-9: 279.5] | Phase 3 | [1] | |
| Company |
Novo Nordisk
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XIII (F13B) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Common Pathway of Fibrin Clot Formation | |||
| WikiPathways | Human Complement System | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Novo Nordisk A/S. | |||
| REF 2 | Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.